Growing community of inventors

Daejeon, South Korea

Hyeon-Kyu Lee

Average Co-Inventor Count = 9.00

ph-index = 1

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 0

Hyeon-Kyu LeeDong-Gyun Kim (1 patent)Hyeon-Kyu LeeBong-Jin Lee (1 patent)Hyeon-Kyu LeeSang Jae Lee (1 patent)Hyeon-Kyu LeeJoo Youn Lee (1 patent)Hyeon-Kyu LeeHyoun Sook Kim (1 patent)Hyeon-Kyu LeeKwan-Young Jeong (1 patent)Hyeon-Kyu LeeKyu-Yeon Lee (1 patent)Hyeon-Kyu LeeHeui Cherl Yang (1 patent)Hyeon-Kyu LeeHyeon-Kyu Lee (1 patent)Dong-Gyun KimDong-Gyun Kim (15 patents)Bong-Jin LeeBong-Jin Lee (5 patents)Sang Jae LeeSang Jae Lee (4 patents)Joo Youn LeeJoo Youn Lee (4 patents)Hyoun Sook KimHyoun Sook Kim (1 patent)Kwan-Young JeongKwan-Young Jeong (1 patent)Kyu-Yeon LeeKyu-Yeon Lee (1 patent)Heui Cherl YangHeui Cherl Yang (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Seoul National University (1 from 1,557 patents)

2. Korea Research Institute of Chemical Technology (1 from 623 patents)

3. National Cancer Center (1 from 222 patents)


1 patent:

1. 12221426 - Inhibitory material against human body-derived nicotinamide adenine dinucleotide phosphate-dependent steroid dehydrogenase-like, and anticancer agent comprising same as effective ingredient or pharmaceutical composition comprising same as effective ingredient for treatment of hyperlipidemia

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/5/2025
Loading…